相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes
Tom C. Karagiannis et al.
AGING-US (2010)
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Paul A. Marks
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Cliona Grant et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Nonhistone protein acetylation as cancer therapy targets
Brahma N. Singh et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Interaction of Daunomycin with Acetylated Chromatin
Lyndsay Sprigg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
γH2AX: a sensitive molecular marker of DNA damage and repair
L-J Mah et al.
LEUKEMIA (2010)
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents
Mandana Namdar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential
Zoya N. Demidenko et al.
AGING-US (2009)
Growth and aging: a common molecular mechanism
Mikhail V. Blagosklonny et al.
AGING-US (2009)
Development of vorinostat: Current applications and future perspectives for cancer therapy
Victoria M. Richon et al.
CANCER LETTERS (2009)
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
Ailsa J. Frew et al.
CANCER LETTERS (2009)
Rapamycin decelerates cellular senescence
Zoya N. Demidenko et al.
CELL CYCLE (2009)
H2AX: functional roles and potential applications
Jennifer S. Dickey et al.
CHROMOSOMA (2009)
Rational Combinations Using HDAC Inhibitors
Michael Bots et al.
CLINICAL CANCER RESEARCH (2009)
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Pamela Munster et al.
CLINICAL CANCER RESEARCH (2009)
Histone Deacetylase Inhibitors: Potential in Cancer Therapy
P. A. Marks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes
Jiahao Liu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments
K. N. Harikrishnan et al.
CELL CYCLE (2008)
Histone deacetylase inhibitors in lymphoma and solid malignancies
Walid Rasheed et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors
Hong Su et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells
Beshay N. M. Zordoky et al.
VASCULAR PHARMACOLOGY (2008)
Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death
Ei Ikegami et al.
CIRCULATION JOURNAL (2007)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments
T. C. Karagiannis et al.
ONCOGENE (2007)
被撤回的出版物: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
Chang-Shi Chen et al.
CANCER RESEARCH (2007)
Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-κB activation
Do-Sung Kim et al.
LIFE SCIENCES (2007)
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
T. C. Karagiannis et al.
LEUKEMIA (2007)
Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure
Julie R. McMullen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2007)
Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: Involvement of the phosphoinositide 3-kinase-Akt pathway
Kevyn E. Merten et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
DNA damage is an early event in doxorubicin-induced cardiac myocyte death
Thomas L'Ecuyer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
The Epigenetic Modifier, Valproic Acid, Enhances Radiation Sensitivity
Tom C. Karagiannis et al.
EPIGENETICS (2006)
Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin
K Li et al.
CIRCULATION (2006)
Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart -: Relative importance of vesicular sequestration and impaired efficiency of electron addition
E Salvatorelli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Multiple actions of pifithrin-alpha on doxorubicin- induced apoptosis in rat myoblastic H9c2 cells
Chu Chang Chua et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase
DS Kim et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity
A Munshi et al.
CLINICAL CANCER RESEARCH (2005)
The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of γH2A.X
TC Karagiannis et al.
CANCER BIOLOGY & THERAPY (2005)
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4
HE Mohamed et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro
P Spallarossa et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2004)
Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors
CL Antos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Cardiac hypertrophy: The good, the bad and the ugly
N Frey et al.
ANNUAL REVIEW OF PHYSIOLOGY (2003)
Lifetime risk for developing congestive heart failure - The Framingham Heart Study
DM Lloyd-Jones et al.
CIRCULATION (2002)
分享论文
